Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 17/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.43 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1491334 | 1.00 | HDAC1 (0.57) | HDAC1HDAC6HDAC3HDAC4HDAC7 | |
| SCHEMBL1491663 | 0.90 | HDAC1 (0.54) | HDAC1HDAC6HDAC3HDAC4HDAC7 | |
| SCHEMBL1491658 | 0.90 | HDAC1 (0.54) | HDAC1HDAC6HDAC3HDAC4HDAC7 | |
| SCHEMBL1491686 | 0.89 | HDAC1 (0.53) | HDAC1HDAC6HDAC3HDAC4HDAC7 | |
| SCHEMBL1491680 | 0.89 | HDAC1 (0.53) | HDAC1HDAC6HDAC3HDAC4HDAC7 | |
| SCHEMBL1491523 | 0.88 | HDAC1 (0.52) | HDAC1HDAC6HDAC3HDAC4HDAC7 | |
| SCHEMBL1491515 | 0.88 | HDAC1 (0.52) | HDAC1HDAC6HDAC3HDAC4HDAC7 | |
| SCHEMBL1491517 | 0.88 | HDAC1 (0.52) | HDAC1HDAC6HDAC3HDAC4HDAC7 | |
| SCHEMBL1491440 | 0.87 | HDAC1 (0.55) | HDAC1HDAC6HDAC3HDAC4HDAC7 | |
| SCHEMBL14911140 | 0.87 | HDAC1 (0.55) | HDAC1HDAC6HDAC3HDAC4HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133104-B2 | Enzyme inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2015-09-15 | — | — | US | disclosed |
| US-20140163042-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2014-06-12 | — | — | US | disclosed |
| US-20140163042-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2014-06-12 | — | — | US | disclosed |
| US-20130116318-A1 | Enzyme Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2013-05-09 | — | — | US | disclosed |
| US-20130116318-A1 | Enzyme Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2013-05-09 | — | — | US | disclosed |
| US-7939666-B2 | Enzyme inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2011-05-10 | — | — | US | disclosed |
| US-7939666-B2 | Enzyme inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2011-05-10 | — | — | US | disclosed |
| US-7939666-B2 | Enzyme inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2011-05-10 | — | — | US | disclosed |
| EP-2301939-A1 | Enzyme inhibitors | Chroma Therapeutics Limited (GB) | 2011-03-30 | — | — | EP | disclosed |
| EP-2301939-A1 | Enzyme inhibitors | Chroma Therapeutics Limited (GB) | 2011-03-30 | — | — | EP | disclosed |
| US-20090291978-A1 | Enzyme Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2009-11-26 | — | — | US | disclosed |
| US-20090291978-A1 | Enzyme Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2009-11-26 | — | — | US | disclosed |
| US-20090291978-A1 | Enzyme Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2009-11-26 | — | — | US | disclosed |
| EP-1879895-A1 | ENZYME INHIBITORS | Chroma Therapeutics Limited (GB) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006117549-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD (GB) | 2006-11-09 | — | — | WO | disclosed |
| WO-2006117549-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD (GB) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116318-A1 | Enzyme Inhibitors | HDAC1, HDAC11, HDAC7 | HDAC1 1/4885HDAC6 11/4885HDAC3 7/4885 |
| US-20140163042-A1 | ENZYME INHIBITORS | HAT1, NR2E1, HDAC3 | HDAC1 5/4885HDAC6 557/4885HDAC3 3/4885 |
| US-20090291978-A1 | Enzyme Inhibitors | HAT1, NR2E1, NR2C2 | HDAC1 9/4885HDAC6 1058/4885HDAC3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.